Wiener klinische Wochenschrift

, Volume 128, Issue 3–4, pp 156–163 | Cite as

Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer

  • Anton PonholzerEmail author
  • Wolfgang Loidl
  • Jasmin Bektic
  • Karl Dorfinger
  • Stephan Hruby
  • Klaus Jeschke
  • Gero Kramer
  • Steffen Krause
  • Georg Ludvik
  • Mesut Remzi
  • Michael Roider
  • Franz Stoiber
consensus report


In recent years, new therapeutic options have brought improvements in the treatment of metastatic, castration-resistant prostate cancer. Targeted Hormone Therapy (THT) represents a novel therapeutic component for which recent studies have shown a maximum benefit in the time between failure of androgen deprivation therapy (patient is metastatic and still pain-free) and prior to chemotherapy. Prostate cancer experts of the Austrian Society of Urology and Andrology (ÖGU), the Working Group for Urologic Oncology as part of the ÖGU, and the Professional Association of Austrian Urologists (BvU) have developed recommendations for the treatment of patients with asymptomatic or mildly symptomatic metastatic, castration-resistant prostate cancer. The definition of failure of classical hormonal therapy has been based on the guidelines of the German Society of Urology (Deutsche Gesellschaft für Urologie, DGU) and the European Association of Urology (EAU). Criteria for the initiation of treatment with hormonal or chemotherapy include:

  • Castration resistance with increase of prostate-specific antigen (PSA)

  • Evidence of metastases in imaging

  • No or mild symptoms

  • Quality of Life Index of the Eastern Cooperative Oncology Group (ECOG) 0-1 (ECOG 2 requires individualized decision) [1].

Treatment should only be initiated when all of these four criteria are applicable, with the age of the patient being no exclusion criterion. First-line therapies for these patients include abiraterone, enzalutamide, and docetaxel as well as radium-223. The manuscript refers only to treatment regimens available in Austria.

Selection of the initial treatment option—starting with THT or chemotherapy—should be determined based on the individual patient characteristics. When using abiraterone or enzalutamide, re-staging within 3–6 months is recommended.


Metastatic, castration-resistant prostate cancer Treatment sequence Targeted Hormone Therapy Abiraterone Enzalutamide 



Androgen deprivation therapy


Alanine transaminase


Alkaline phosphatase


Androgen receptor splice variant-7


Aspartate transaminase


American Urological Association


Working Group of Urologic Oncology (Arbeitskreis für Urologische Onkologie)


Professional Association of Austrian Urologists (Berufsverband der Österreichischen Urologen)


C-reactive protein


Castration-resistant prostate cancer




German Society of Urology (Deutsche Gesellschaft für Urologie)


European Association of Urology


Quality of Life Index of the Eastern Cooperative Oncology Group


European Society for Medical Oncology

Hb drop

Hemoglobin drop


Lactate dehydrogenase


Metastatic, castration-resistant prostate cancer


Magnetic resonance imaging


Austrian Society of Urology and Andrology (Österreichische Gesellschaft für Urologie und Andrologie)


Overall survival


Prostate cancer


Positron emission tomography


Progression-free survival


Prostate-specific antigen


Response Evaluation Criteria in Solid Tumors


Radiographic progression-free survival


Targeted Hormone Therapy


Compliance with ethical standards

Conflict of interests

The technical organization and conduct of the consensus meeting and the subsequent coordination process as well as the publication of the consensus statements have been facilitated by the company Janssen, though without any influence on the content. The authors declare that there has been no conflict of interests with regard to the publication of this article.


  1. 1.
    Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16(2):152–60. doi: 10.1016/S1470-2045(14)71205-7.CrossRefPubMedGoogle Scholar
  2. 2.
    Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol. 2008;617:223–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120:2715–30.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15(15):4792–8.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Mostaghel EA, Nelson PS, Lange P, et al. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014;32:229–37.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Heidenreich A, et al. European Association of Urology Guidelines on Prostate cancer 2009,
  7. 7.
    Scher HI, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506.CrossRefPubMedGoogle Scholar
  10. 10.
    Scher HI, et al. Increased Survival with Enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Horwich A, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;00:1–22.Google Scholar
  12. 12.
    Heidenreich A, et al. EAU guidelines on prostate cancer. Europ Urol. 2011;59(4):572–83.CrossRefGoogle Scholar
  13. 13.
    Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33. doi: 10.1056/NEJMoa1405095.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Tombal B, et al. Enzalutamide in Men with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated Overall Survival Analysis of the Phase 3 PREVAIL Study. EAU 20.-24.3.2015 Madrid, Oral Presentation.Google Scholar
  15. 15.
    Antonarakis ES, et al. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. N Engl J Med. 2014;371:1028–38. doi: 10.1056/NEJMoa1315815.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    M Stein. ASCO Annual Meeting. 2014. (30.5–3.6.2014), Oral Presentation.Google Scholar
  17. 17.
    De Bono J, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Parker C, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol. 2012;30(5):abstract LBA 4512.Google Scholar
  19. 19.
    Mottet N, et al. European Association of Urology Guidelines on Prostate cancer,
  20. 20.
    National Cancer Institute (14.06.2010).×7.pdf (abgerufen am 15.07.2014).
  21. 21.
    S3-Leitlinie Prostatakarzinom ILeitliniederQS3zurF. Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Version 3.0, September 2014, AWMF-Register-Nummer 043/022OL.Google Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Anton Ponholzer
    • 1
    Email author
  • Wolfgang Loidl
    • 2
  • Jasmin Bektic
    • 3
  • Karl Dorfinger
    • 4
  • Stephan Hruby
    • 5
  • Klaus Jeschke
    • 6
  • Gero Kramer
    • 7
  • Steffen Krause
    • 8
  • Georg Ludvik
    • 9
  • Mesut Remzi
    • 10
  • Michael Roider
    • 11
  • Franz Stoiber
    • 12
  1. 1.Department of Urology and Andrology, Working Group Urologic Oncology (AUO)Hospital Barmherzige Brüder ViennaViennaAustria
  2. 2.Department of Urology, Austrian Society of Urology and Andrology (ÖGU)Hospital Barmherzige Schwestern LinzLinzAustria
  3. 3.European Prostate CenterUniversity Hospital of UrologyInnsbruckAustria
  4. 4.Urology and Andrology in ViennaProfessional Association of Austrian Urologists (BvU)ViennaAustria
  5. 5.Urology and AndrologyUniversity HospitalSalzburgAustria
  6. 6.Department of Urology and AndrologyClinic Center Klagenfurt am WörtherseeKlagenfurt am WörtherseeAustria
  7. 7.Urologic Outpatient Tumor UnitUniversity Hospital of UrologyViennaAustria
  8. 8.Department of UrologyGeneral Hospital of the City of LinzLinzAustria
  9. 9.Urology & AndrologyViennaAustria
  10. 10.Department of UrologyProvincial Hospital KorneuburgKorneuburgAustria
  11. 11.KABEGClinic Center Klagenfurt am WörtherseeKlagenfurt am WörtherseeAustria
  12. 12.Department of UrologyProvincial Hospital VöcklabruckVöcklabruckAustria

Personalised recommendations